GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
February 26 2021 - 4:30PM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that
executives from the Company plan to participate in three virtual
healthcare conferences in March. More information about the
presentations and panel discussions will be available on the
Company’s website, under the Investors tab. Details are as
follows:
Cowen 41st Annual Health Care
Conference March 1 – March 4, 2021 Eric Feldman, M.D.,
GlycoMimetics Vice President, Clinical Development, to participate
in Leukemias Panel Wed, March 3, 2021, 11:40 a.m. – 12:40 p.m.
(EST) Access to the panel discussion is for registered attendees
only.
H.C. Wainwright Global Life Sciences
Conference March 9 – 10, 2021 Rachel King, GlycoMimetics CEO,
to present a corporate overview The presentation will be available
on-demand, beginning at 7 a.m. ET, March 9 through March 10. Access
will be provided through the Company’s website (Investors section)
and archived for 90 days.
33rd Annual Virtual Roth Conference
March 15 – 17, 2021 Rachel King, GlycoMimetics CEO, to present a
corporate overview Mon, March 15, 10:00 a.m. – 12:00 p.m. (EST) in
Virtual 2 (Panel: Navigating Clinical Development in Rare
Hematology & Inflammatory Disease). A link to the panel session
will be available in the Investors section of the GlycoMimetics
website.
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with a focus in
hematology-oncology and a pipeline of novel glycomimetic drugs, all
designed to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics’ drug
candidate, uproleselan, an E-selectin antagonist, was evaluated in
a Phase 1/2 clinical trial as a potential treatment for AML and is
being evaluated across a range of patient populations including in
a Company-sponsored Phase 3 trial in relapsed/refractory AML under
Breakthrough Therapy Designation. Rivipansel, a pan-selectin
antagonist, is being explored for use in treatment of acute VOC in
sickle cell disease. GlycoMimetics has also completed a Phase 1
clinical trial with another wholly-owned drug candidate, GMI-1359,
a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210226005644/en/
Investor: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media: Jamie Lacey-Moreira Phone: 410-299-3310 Email:
jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Sep 2023 to Sep 2024